靶向“不可成药”蛋白的最新进展:从药物发现到临床试验。

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.

机构信息

State Key Laboratory of Southwestern Chinese Medicine Resources, College of Medical Technology and School of Pharmacy, Chengdu University of Traditional Chinese Medicine, 611137, Chengdu, China.

Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.

出版信息

Signal Transduct Target Ther. 2023 Sep 6;8(1):335. doi: 10.1038/s41392-023-01589-z.

Abstract

Undruggable proteins are a class of proteins that are often characterized by large, complex structures or functions that are difficult to interfere with using conventional drug design strategies. Targeting such undruggable targets has been considered also a great opportunity for treatment of human diseases and has attracted substantial efforts in the field of medicine. Therefore, in this review, we focus on the recent development of drug discovery targeting "undruggable" proteins and their application in clinic. To make this review well organized, we discuss the design strategies targeting the undruggable proteins, including covalent regulation, allosteric inhibition, protein-protein/DNA interaction inhibition, targeted proteins regulation, nucleic acid-based approach, immunotherapy and others.

摘要

不可成药蛋白是一类蛋白质,其通常具有较大、复杂的结构或功能,使用传统的药物设计策略难以对其进行干扰。针对这些不可成药靶点的治疗方法被认为是人类疾病治疗的一个重大机遇,并且在医学领域吸引了大量的研究。因此,在这篇综述中,我们重点关注针对“不可成药”蛋白的药物发现的最新进展及其在临床中的应用。为了使这篇综述组织有序,我们讨论了针对不可成药蛋白的设计策略,包括共价调节、别构抑制、蛋白-蛋白/DNA 相互作用抑制、靶向蛋白调节、基于核酸的方法、免疫疗法等。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405f/10480221/5c68c7c48cf2/41392_2023_1589_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索